Search

Stradling

Santen Pharmaceuticals Completes Acquisition of Asia Rights for Ophthalmic Pharmaceutical From MacuSight

Santen Pharmaceutical Co. Ltd.

Represented Santen Pharmaceutical Co. Ltd. in its acquisition of Asia Rights to Sirolimus for Ophthalmology from MacuSight for $50 million upfront, plus milestones and royalties.